

Special Issue

Gram-Negative Multidrug-Resistant Pathogens and Their Treatment, 2nd Edition

Message from the Guest Editor

The first edition of the Special Issue “Gram-Negative Multidrug Resistant Pathogen and Its Treatment” was closed in 2023. As a continuation, this second edition continues to explore the development of new antibiotics combating carbapenemase-producing

Enterobacteriaceae (CPE), multidrug-resistant (MDR), and extensively drug-resistant (XDR) strains of *Pseudomonas aeruginosa*. We welcome research articles and reviews on topics including antibiotic resistance epidemiology, particularly in rural areas of low-income countries, antimicrobial therapy, clinical strategies, and so on. New Focus Areas:

Epidemiological studies on the spread of antimicrobial resistance in low-resource settings; Socioeconomic factors influencing antibiotic misuse and resistance; A One Health approach to understanding the interplay between human, animal, and environmental health in the context of antimicrobial resistance; Clinical strategies for managing infections caused by MDR and XDR pathogens.

Guest Editor

Dr. Ramón Pérez-Tanoira

1. Department of Microbiology, Hospital Universitario Príncipe de Asturias, 28805 Madrid, Spain
2. Department of Biomedicine and Biotechnology, Universidad de Alcalá, 28801 Alcalá de Henares, Spain

Deadline for manuscript submissions

31 December 2025



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/235268

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)